Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 14 January 2013 | By Ansis Helmanis,
China's State Food and Drug Administration (SFDA), the National Development and Reform Commission, the Ministry of Industry and Information Technology, and the Ministry of Health issued on 21 December 2012, a joint notice to the provinces and municipalities setting forth deadlines for implementation of the revised good manufacturing practices (GMPs) by the pharmaceutical industry.
Injectable drug manufacturers must implement the revised GMPs by 1 January 2014, and the manufacturers of other drugs must do so by 1 January 2016. The notice also recommends that authorities responsible for setting drug prices should consider the cost of GMP compliance when making product-pricing decisions.
Read all Breaking News from RegLink
Tags: Implementation, Injectable, SFDA, manufacturer, pharmaceutical, drug, GMP